Charles Schwab Investment Management Inc Glycomimetics Inc Transaction History

Charles Schwab Investment Management Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$0.57 - $3.03 $12,745 - $67,753	22,361 New	22,361 $67,000
Q2 2022 Aug 15, 2022	BUY	$0.54 - $1.15 $32,590 - $69,405	60,353 New	60,353 $37,000
Q1 2022 May 13, 2022	SELL	$1.0 - $1.58 $34,903 - $55,146	-34,903 Closed	0 $0
Q3 2021 Nov 16, 2021	BUY	$1.8 - $2.39 $42,265 - $56,119	23,481 Added 205.58%	34,903 $77,000
Q2 2021 Aug 16, 2021	SELL	$2.16 - $3.18 $164,689 - $242,459	-76,245 Reduced 86.97%	11,422 $27,000
Q3 2020 Nov 13, 2020	SELL	$3.07 - $5.0 $1,492 - $2,430	-486 Reduced 0.55%	87,667 $270,000
Q2 2020 Aug 14, 2020	BUY	$2.06 - $3.76 $13,120 - $23,947	6,369 Added 7.79%	88,153 $332,000
Q2 2019 Aug 09, 2019	BUY	$10.6 - $13.12 $33,464 - $41,419	3,157 Added 4.02%	81,784 $975,000
Q1 2019 May 14, 2019	BUY	$9.96 - $13.44 $22,330 - $30,132	2,242 Added 2.94%	78,627 $980,000
Q3 2018 Nov 13, 2018	BUY	$13.7 - $17.12 $32,373 - $40,454	2,363 Added 3.19%	76,385 $1.1 Million
Q2 2018 Aug 08, 2018	BUY	$14.63 - $19.19 $1.08 Million - $1.42 Million	74,022 New	74,022 $1.19 Million

17.8M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $16.8M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.